Merus (NASDAQ:MRUS) Trading Down 7.6% - Should You Sell?

Merus (NASDAQ:MRUS - Get Free Report)'s share price was down 7.6% during mid-day trading on Monday . The stock traded as low as $39.00 and last traded at $41.20. Approximately 332,799 shares traded hands during trading, a decline of 52% from the average daily volume of 686,506 shares. The stock had previously closed at $44.61.

Analyst Ratings Changes

Several research analysts have recently commented on the company. William Blair reissued an "outperform" rating on shares of Merus in a report on Friday, February 28th. Citigroup increased their price objective on shares of Merus from $89.00 to $97.00 and gave the stock a "buy" rating in a report on Monday, December 9th. Bank of America reduced their target price on shares of Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. HC Wainwright reissued a "buy" rating and issued a $85.00 price target on shares of Merus in a report on Monday, March 3rd. Finally, Piper Sandler began coverage on Merus in a report on Thursday, February 13th. They set an "overweight" rating and a $84.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $85.31.

Merus Stock Down 8.7 %

The firm has a market cap of $2.63 billion, a P/E ratio of -9.65 and a beta of 1.02. The business has a fifty day moving average of $44.09 and a 200 day moving average of $45.86.

Remove Ads

Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.48. The company had revenue of $9.14 million during the quarter, compared to analysts' expectations of $10.57 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. On average, sell-side analysts expect that Merus will post -3.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Merus

Several institutional investors and hedge funds have recently made changes to their positions in MRUS. State of Wyoming acquired a new stake in Merus during the 4th quarter worth $48,000. Wells Fargo & Company MN raised its position in shares of Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 300 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Merus during the fourth quarter worth about $60,000. Avior Wealth Management LLC bought a new position in shares of Merus during the 4th quarter valued at about $76,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Merus in the 4th quarter valued at approximately $84,000. Institutional investors and hedge funds own 96.14% of the company's stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.